RPG Life Sciences Ltd
₹ 2,179
1.10%
10 Jun
- close price
About
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
Key Points
- Market Cap ₹ 3,603 Cr.
- Current Price ₹ 2,179
- High / Low ₹ 2,977 / 1,457
- Stock P/E 30.5
- Book Value ₹ 321
- Dividend Yield 0.73 %
- ROCE 33.3 %
- ROE 26.1 %
- Face Value ₹ 8.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 29.1% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.4%
- Company has been maintaining a healthy dividend payout of 27.1%
Cons
- The company has delivered a poor sales growth of 11.7% over past five years.
- Earnings include an other income of Rs.95.3 Cr.
- Debtor days have increased from 35.3 to 48.5 days.
- Working capital days have increased from 57.7 days to 115 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | |
| 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 494 | |
| Operating Profit | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 160 |
| OPM % | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 24% |
| 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | |
| Interest | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 |
| Profit before tax | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 |
| Tax % | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% |
| 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | |
| EPS in Rs | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 |
| Dividend Payout % | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 29% |
| 3 Years: | 32% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 52% |
| 3 Years: | 62% |
| 1 Year: | 42% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 26% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 |
| 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | |
| 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | |
| Total Liabilities | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
| 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 184 | |
| CWIP | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 |
| 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | |
| Total Assets | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6 | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 | |
| 59 | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 | |
| -54 | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | -17 | -20 | -27 | |
| Net Cash Flow | 0 | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 |
| Inventory Days | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 |
| Days Payable | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 |
| Cash Conversion Cycle | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 |
| Working Capital Days | 51 | 76 | 54 | 50 | 62 | 53 | 46 | 53 | 47 | 33 | 25 | 115 |
| ROCE % | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% |
Documents
Announcements
-
Email Communication To Shareholders Regarding Dividend Taxation Provisions
5 Jun - Board recommends Rs.20 final and Rs.4 special dividend for FY24-25, with tax deduction details for shareholders.
-
Intimation To Shareholders Holding Shares In Physical Mode Regarding Furnishing Of PAN, KYC Details And Nomination
3 Jun - Reminder to physical shareholders to update PAN, KYC, nomination as per SEBI regulations.
-
Further To Our Letter Dated April 28, 2025 We Enclose Herewith Updated Annexure C Pursuant To Details Required As Per SEBI Circular No. SEBI/HO/CFD/CFD-Pod-1/P/CIR/2023/123 Dated July 13,2023.
3 Jun - Appointed Mr. Yugal Sikri as Non-Executive Non-Independent Director effective May 1, 2025.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2 Jun - In continuation of letter May 29, 2025 and pursuant to regulation 30 of SEBI LODR, 2015 the investor presentation which will be made during the …
-
In Accordance With Regulation 30 Of SEBI (LODR) Regulations, 2015 ("Listing Regulations"), To Shareholders Whose Shares Are Liable To Be Transferred To IEPF Authority.
1 Jun - Shares with unclaimed dividends since FY 2017-18 to transfer to IEPF by Aug 25, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Jun 2025TranscriptNotesPPT
-
Apr 2025Transcript PPT REC
-
Nov 2024TranscriptNotesPPT
-
Sep 2024TranscriptPPTREC
-
Jul 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Oct 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptNotesPPT
Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs